Abstract:Importance: MUC16, which encodes cancer antigen 125 (CA-125), is frequently mutated in gastric cancer (GC); however, its association with tumor mutation load (TML) and outcome in patients with GC has not been established, to date.Objective: To investigate whether MUC16 mutations are associated with TML and prognosis in patients with GC.Design, Setting, and Participants: Statistical analysis of genomic data from 437 GC samples obtained from The Cancer Genome Atlas (TCGA) and 256 samples from an Asian cohort. Both cohorts contained data of patients with GC involved in previous genomic studies. Data were obtained from TCGA on September 3, 2017, and from the Asian cohort on March 5, 2013, and analyzed from September 3 to December 1, 2017. The TCGA cohort was used as a discovery set and the Asian cohort as a validation set. Kaplan-Meier survival analysis and multivariate Cox and logistic regression models were applied. Regression models addressed confounding factors; Bayesian variant nonnegative matrix factorization was used to extract mutational signatures. The MutSigCV algorithm was used to identify significantly mutated genes.Main Outcomes and Measures: Primary outcomes were mutation frequency, overall survival, and TML, calculated using Kaplan-Meier survival analysis, odds ratios (ORs), and significance of signaling pathways.Results: MUC16 was mutated in 168 of 437 (38.4%) of the GC samples from the TCGA cohort and in 57 of 256 (22.3%) from the Asian cohort. In both cohorts, GC samples with MUC16 mutations exhibited significantly greater TML than those without MUC16 mutations (median mutation counts: TCGA cohort, 264 with MUC16 mutation vs 115 without; Asian cohort, 134 with MUC16 mutation vs 74 without; Wilcoxon rank sum test, both P < .001). This association was independent of mutations in POLE and BRCA1/2 and mutational signatures in the TCGA cohort (OR, 1.87; 95% CI, 1.49-2.36; P < .001) and the Asian cohort (OR, 1.69; 95% CI, 1.25-2.29; P < .001). MUC16 mutations were significantly associated with better prognosis in both cohorts (median overall survival, 46.9 [95% CI, 26.4-NA (not available)] vs 26.7 [95% CI, 20.2-43.1] months; log-rank test, P = .007 [TCGA cohort] and not calculable [the median overall survival of patients with GC and MUC16 mutations could not be calculated because more than half the patients in the group were alive] vs 36.8 months; P = .04 [Asian cohort]). The association remained statistically significant after controlling for age, sex, TNM stage, mutations in POLE and BRCA1/2, and mutational signatures (hazard ratio, 0.61 [95% CI, 0.42-0.89]; log rank test, P = .01). Immune response and cell cycle regulation circuits were among the top altered signaling pathways in samples with MUC16 mutations (normalized enrichment score, 1.70 [95% CI, 1.57-1.79] and 2.04 [95% CI, 1.90-2.18]; adjusted P < .001). The prognostic significance of MUC16 mutation identified in the TCGA cohort was validated in the Asian cohort.Conclusions and Relevance: These findings indicate that MUC16 mutations may be associated with higher TML, better survival outcomes, and immune response and cell cycle pathways. These findings may be immediately applicable for guiding immunotherapy treatment for patients with GC.

Mucin 16 Promotes Colorectal Cancer Development and Progression Through Activation of Janus Kinase 2

C-terminus of MUC16 Activates Wnt Signaling Pathway Through Its Interaction with Β-Catenin to Promote Tumorigenesis and Metastasis

Mutation of MUC16 Is Associated With Tumor Mutational Burden and Lymph Node Metastasis in Patients With Gastric Cancer

MUC1 and MUC16: critical for immune modulation in cancer therapeutics

Role of MUC20 overexpression as a predictor of recurrence and poor outcome in colorectal cancer

MUC16 stimulates neutrophils to an inflammatory and immunosuppressive phenotype in ovarian cancer

RUNX1-MUC13 Interaction Activates Wnt/β-Catenin Signaling Implications for Colorectal Cancer Metastasis

MUC21 controls melanoma progression via regulating SLITRK5 and hedgehog signaling pathway

Mucin 17 Inhibits the Progression of Human Gastric Cancer by Limiting Inflammatory Responses Through a MYH9-p53-RhoA Regulatory Feedback Loop

Why MUC16 Mutations Lead to a Better Prognosis: A Study Based on the Cancer Genome Atlas Gastric Cancer Cohort

Mucin 1 promotes tumor progression through activating WNT/β-catenin signaling pathway in intrahepatic cholangiocarcinoma

Mucin 2 silencing promotes colon cancer metastasis through interleukin-6 signaling

MUC13 promotes the development of colitis-associated colorectal tumors via β-catenin activity

MUC16 C terminal fragment activates YAP1 through Src signaling to promote gallbladder cancer growth

Mucin 1 promotes salivary gland cancer cell proliferation and metastasis by regulating the epidermal growth factor receptor signaling pathway

MUC16 Promotes Liver Metastasis of Pancreatic Ductal Adenocarcinoma by Upregulating NRP2-Associated Cell Adhesion

Muc16 Carboxyl Portion Expression Alternates PI3K/Akt and EGFR/HER2/ERK Signal Pathways in Human Ovarian Cells

Association of MUC16 Mutation With Tumor Mutation Load and Outcomes in Patients With Gastric Cancer

MUC1 Induces Metastasis in Esophageal Squamous Cell Carcinoma by Upregulating Matrix Metalloproteinase 13

Mucin1 shifts Smad3 signaling from the tumor-suppressive pSmad3C/p21(WAF1) pathway to the oncogenic pSmad3L/c-Myc pathway by activating JNK in human hepatocellular carcinoma cells.

Mucin1 mediates autocrine transforming growth factor beta signaling through activating the c-Jun N-terminal kinase/activator protein 1 pathway in human hepatocellular carcinoma cells.